Skip to content

Analgesia in Minimally Invasive Direct Coronary Artery Bypass Grafting: Programmed Intermittent Bolus Infusions of Erector Spinae Plane Block Versus Paravertebral Block

Comparison of Programmed Intermittent Bolus Infusions of Spinae Plane Block Versus Paravertebral Block for Analgesia in Minimally Invasive Direct Coronary Artery Bypass Grafting

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05320718
Enrollment
140
Registered
2022-04-11
Start date
2022-04-15
Completion date
2023-12-30
Last updated
2026-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Local, Regional Anesthesia, Surgery

Brief summary

Paravertebral block (PVB) has been regarded as effective regimen for pain control after cardiac surgery. As a novel analgesia technique, erector spinae plane block (ESPB) has been reported to provide effective analgesia after thoracic and cardiac surgery. We hypothesized that the ESPB is non-inferior to PVB in treating pain in minimally invasive direct coronary artery bypass surgery.

Detailed description

Minimally invasive direct coronary artery bypass grafting has recently gained with popularity in treatment of coronary artery disease. Compared with conventional approach, it has advantages of less trauma and rapid recovery, but postoperative pain is severe, which may increase the risk of cardiopulmonary complications and cause chronic pain. Therefore, perioperative analgesia is crucial in minimally invasive direct coronary artery bypass grafting. Paravertebral block (PVB) has been regarded as effective regimen for pain control after cardiac surgery. As a novel analgesia technique, erector spinae plane block (ESPB) has been reported to provide effective analgesia after thoracic and cardiac surgery. We hypothesized that the ESPB is non-inferior to PVB in treating pain in minimally invasive direct coronary artery bypass surgery.

Interventions

DRUGRopivacaine

20 ml of 0.5% ropivacaine as bolus and a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery

Sponsors

Peking University Third Hospital
Lead SponsorOTHER
Beijing Municipal Health Commission
CollaboratorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* patients undergoing elective minimally invasive direct coronary artery bypass grafting

Exclusion criteria

1. Contraindications to regional anesthesia (coagulopathy, infection of the skin at the site of needle puncture area, et al) 2. Morbid obesity (body mass index \> 35 kg/m2) 3. Allergy to any of the study drugs 4. Chronic opioid use or history of opioid abuse. 5. Inability to understand pain score

Design outcomes

Primary

MeasureTime frameDescription
pain at cough after surgerypostoperatively 0-3 dayNumerical Rating Pain Scale, where 0=No Pain (better outcome) and 10=Intractable Pain (worse outcome)
postoperative rescue analgesic consumptionpostoperatively 0-3 daymorphine equivalents

Secondary

MeasureTime frameDescription
pain at rest after surgerypostoperatively 0-3 dayNumerical Rating Pain Scale, where 0=No Pain (better outcome) and 10=Intractable Pain (worse outcome)
adverse events of regional blockIntraoperative (during and immediately after block performance)local bleeding, pleural puncture, local anesthetic toxicity
dermatome of blockimmediately after extubationloss of cold sensation (ice cubes), 3-point scale: 0 = loss of cold sensation, 1=decreased cold sensation, 2 = normal sensation.

Countries

China

Contacts

PRINCIPAL_INVESTIGATORMin Li, MD

Peking University Third Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 24, 2026